Ortho RTI submitted an investigational new drug application to begin phase 1 and 2 trials for Ortho-R. The FDA requested additional information related to chemistry, manufacturing and control. Ortho RTI plans to provide the information and testing data to the FDA within the next four to six weeks.
“We will work diligently to address the FDA’s questions as quickly as possible and look forward to continuing to work closely with them to secure IND approval,” president and CEO Claude LeDuc said.
Last year, Ortho-R was classified as a biologic drug. Ortho RTI had planned to start clinical trials later this year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
